Consumer Goods » Food, Beverages & Tobacco | Rock Creek Pharmaceuticals Inc.

Rock Creek Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Sales/Revenue
1,722.00
6,188.00
9,141.00
-
-
Cost of Goods Sold (COGS) incl. D&A
3,437.00
3,594.00
5,186.00
156.00
146.00
Gross Income
1,715.00
2,594.00
3,955.00
156.00
146.00
SG&A Expense
36,051.00
25,907.00
36,878.00
27,245.00
11,169.00
EBIT
37,766.00
23,313.00
32,923.00
27,401.00
11,315.00
Unusual Expense
-
1,300.00
2,000.00
5,178.00
4,571.00
Non Operating Income/Expense
5.00
6,600.00
1,680.00
558.00
390.00
Interest Expense
263.00
104.00
-
1.00
410.00
Pretax Income
37,988.00
18,100.00
33,229.00
33,116.00
6,763.00
Consolidated Net Income
37,988.00
18,100.00
33,229.00
33,116.00
6,763.00
Net Income
37,988.00
18,100.00
33,229.00
33,116.00
6,763.00
Net Income After Extraordinaries
37,988.00
13,347.00
33,624.00
27,715.00
6,681.00
Net Income Available to Common
37,988.00
19,769.00
33,229.00
34,899.00
6,845.00
EPS (Basic)
7.00
3.75
5.00
5.22
0.70
Basic Shares Outstanding
5,345.20
5,879.90
6,722.40
7,379.30
9,719.60
EPS (Diluted)
7.11
3.89
4.88
5.22
0.70
Diluted Shares Outstanding
5,345.20
5,879.90
6,722.40
7,379.30
9,719.60
EBITDA
37,403.00
22,981.00
32,606.00
27,245.00
11,169.00
Non-Operating Interest Income
46.00
17.00
14.00
22.00
1.00

About Rock Creek Pharmaceuticals

View Profile
Address
2040 Whitfield Avenue
Sarasota Florida 34243
United States
Employees -
Website -
Updated 07/08/2019
Rock Creek Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health utilizing its proprietary compounds. It focuses on pharmaceutical development activities centered primarily on anatabine citrate as a lead drug candidate. The company was founded by Jonnie R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.